39 results about "Oxacillin Sodium" patented technology

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

The invention discloses a midget anti drug-tolerance staphylococcus aureus polypeptide comprised of passage structure domain to form ion channel colicine and staphylococcus aureu pheromone, as well as opposite coded nucleotide sequence and recombination plasmid contained said sequence. Wherein, the plupeptide can not induce bacteria to generate trsditional drug-tolerance by the mechnism that it forms directly ion channel on cell film of target cell to kill bacteria. This invention has more single antimicrobial spectrum without effect to Gram-negative bacteria of escherichia coli, shows at least 500 times effect to pheneazonecillin, and can be used as synergist to beta-lactam antibiotics.

The invention relates to a method for detecting oxacillin SERS by using superparamagnetic Fe<3>O<4>@SiO<2>@Ag nano composite material. Fe<3>O<4>@SiO<2>@Ag nano composite material is used as SERS active substrate. The preparation method of the SERS active substrate Fe<3>O<4>@SiO<2>@Ag nano composite material takes Fe<3>O<4> as a core and takes SiO<2> as a shell to construct a Fe<3>O<4>@SiO<2> core-shell structure, Ag nano particles are formed by utilizing the isotropic growth of Ag species and the stabilizing action of polyvinylpyrrolidone (PVP) and are deposited on the core-shell structure, the Fe<3>O<4>@SiO<2>@Ag core-shell structure which is good in dispersion, good in magnetic response, high in sensitivity and integrated is obtained. The method for detecting the oxacillin SERS has the advantages of simplicity, rapidness, high integration, good reproducibility and high sensitivity, and can be used for rapidly detecting the oxacillin in various dosage forms.

Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.

The invention provides a method for preparing oxacillin sodium and oxacillin sodium for injection by taking 6-APA and benzyl chloride isoxazole as raw materials, which comprises the steps of condensation, acidification, crystallization, crystal washing, grinding, packaging and the like. The synthesis method of the oxacillin sodium can be stably operated with high efficiency on a large scale, and realizes the synthesis of the oxacillin sodium with high yield, purity and stability on the industrial scale; and furthermore, the method can be used for directly obtaining the oxacillin sodium product for injection by controlling the production environment and process.

The invention belongs to the field of pharmacy, and relates to a benzene polyene sesquiterpene derivative and an application thereof in preparing an anti-resistant-bacteria medicine and preparation, and especially in preparing medicines and preparations used for inhibiting drug-resistant staphylococcus aureus. The benzene polyene sesquiterpene derivative provided by the invention comprises compounds 1 and 2, and is obtained by separation from a traditional Chinese medicine material asafoetida. As a result of test, the derivative has pharmacological activity against drug-resistant staphylococcus aureus. The compound 2 has a minimal inhibitory concentration (MIC) of 2mug/L against tetracycline-resistant staphylococcus aureus strain XU212 and methicillin-resistant staphylococcus aureus strain EMRSA-15, such that the activity is substantially better than control drugs tetracycline and oxacillin. For bacterium drug resistance, the compounds 1 and 2 show significant external pump inhibition effect against resistant staphylococcus aureus RN4220 with MsrA macrolide external pump protein and methicillin-resistant staphylococcus aureus EMRSA-16 with mecA gene. The derivative can be further used for preparing medicine preparations used for resisting external-pump drug-resistant staphylococcus aureus.

The invention relates to a bactericidal composition containing bromothalonil and carbazole, the active ingredient of which is a binary compound of bromothalonil and carbazole. Among them, the mass ratio of bromothalonil to carbendazole is 1-25:25-1, the mass ratio of active ingredients bromothalonil to carbendazole in the preparation is 1%-80%, and the rest are allowed to be used and accepted in pesticides. auxiliary components, the dosage form of the bactericidal composition of the present invention is emulsifiable concentrate, suspension concentrate, wettable powder, water, water dispersible granule, water emulsion, microemulsion, granule, microcapsule. Mainly used to control cucumber, grape downy mildew, botrytis and other diseases.

The invention belongs to the field of pharmacy, and relates to an application of spiroketal polyacetylene compounds in preparing sensitizing medicines for resisting efflux pump resistant staphylococcus aureus. Based upon results of bacteriostasis experiments, the spiroketal polyacetylene compounds, in the mode of a synergistic effect, can generate an antibacterial synergistic action on oxacillin;and especially, through combined use of the spiroketal polyacetylene compounds and the oxacillin, the minimum inhibitory concentration of the oxacillin can be obviously reduced, and a resistant staphylococcus aureus synergistic action can be taken on the oxacillin. The spiroketal polyacetylene compounds can be applied to the sensitizing medicines for resisting a multi-drug resistant staphylococcusaureus strain EMRSA-16 containing an mecA efflux pump drug resistance gene, as well as to a pharmaceutical composition which is prepared from the compounds and the oxacillin and has a resistant staphylococcus aureus resisting effect.

The invention discloses application of vanillic acid in inhibiting growth of multi-drug-resistance staphylococcus aureus. The inhibition effect of the vanillic acid on humanized multi-drug-resistancestaphylococcus aureus is put forward based on the fact that the vanillic acid has a good in-vitro killing effect on humanized multi-drug-resistance staphylococcus aureus which is resistant to linezolid, trimethoprim, gentamicin, ciprofloxacin, penicillin, cefazolin, clindamycin, vancomycin, oxacillin and piperacillin, and can inhibit the growth of multi-drug-resistance staphylococcus aureus, wherein the minimum bactericidal concentration is 2.4 mg/mL, and the minimum inhibitory concentration is 0.3 mg/mL. By means of the vanillic acid, drug-resistance infection of multi-drug-resistance staphylococcus aureus can be effectively relieved or solved, the mortality is reduced, a new idea is put forward for inhibition of humanized multi-drug-resistance staphylococcus aureus, and the vanillic acidhas important practical significance.

The invention discloses an application of 24-membered macrocyclic Schiff base in preparation of a drug for treating methicillin-resistant staphylococcus aureus infection. The 24-membered macrocyclic Schiff base is found to form a G-quadruplex structure with the core sequence of the MecA gene in the methicillin-resistant staphylococcus aureus through methods such as circular dichroism spectrum andWestern-Blot, so that the expression of the corresponding penicillin-binding protein PBP2a is inhibited. Pharmacological sensitivity experiments prove that the 24-membered macrocyclic Schiff base canreduce the minimum inhibitory concentration of methicillin-resistant staphylococcus aureus on oxacillin. When the use amount of the 24-membered macrocyclic Schiff base is 5 [mu] M, the minimum inhibitory concentration of methicillin-resistant staphylococcus aureus can be reduced to 0.5 [mu] g/mL to the minimum, and the effect of treating methicillin-resistant staphylococcus aureus infection by using beta-lactam drugs is achieved.